Viatris (FRA:VIA) Long-Term Debt : €14,787 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Viatris Long-Term Debt?

Viatris's Long-Term Debt for the quarter that ended in Mar. 2024 was €14,787 Mil.

Viatris's quarterly Long-Term Debt declined from Sep. 2023 (€16,001 Mil) to Dec. 2023 (€14,844 Mil) and declined from Dec. 2023 (€14,844 Mil) to Mar. 2024 (€14,787 Mil).

Viatris's annual Long-Term Debt declined from Dec. 2021 (€17,450 Mil) to Dec. 2022 (€17,006 Mil) and declined from Dec. 2022 (€17,006 Mil) to Dec. 2023 (€14,844 Mil).

Viatris Long-Term Debt Historical Data

The historical data trend for Viatris's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Long-Term Debt Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

10,092.87

18,436.80

17,449.63

17,006.35

14,844.49

Viatris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															16,876.82	15,918.06	16,001.06	14,844.49	14,786.70

Viatris (FRA:VIA) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Viatris Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Viatris's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (FRA:VIA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (FRA:VIA) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.